Quantum Cyber N.V. 8K

The company amended its Dutch articles of association to change its name to Quantum Cyber N.V., overhaul its authorized capital and preferred share structure, and define preferred-to-ordinary share conversion terms with transitional capital thresholds.

On April 22, 2026, Mainz Biomed N.V. executed a notarial deed amending its Dutch articles of association to change its corporate name to Quantum Cyber N.V., substantially revise its authorized share capital structure, and clarify the conversion mechanics of multiple series of preferred shares into ordinary shares. The amended articles set a full authorized capital of EUR 10,000,000 divided into 900,000,000 ordinary shares and 100,000,000 preferred shares (series A–E), but introduce transitional provisions under Article 41 that temporarily cap authorized capital at lower levels (EUR 750,000, then EUR 2,500,000) tied to thresholds in the number of issued ordinary shares, with required filings at the Dutch trade register as each threshold is reached. The deed specifies that series A–C preferred shares are convertible at the holder’s option into nine ordinary shares each and series D–E preferred shares into 225 ordinary shares each, with the associated payment obligations primarily funded from series-specific share premium reserves, then other distributable or convertible reserves, and lastly in cash by the holders if reserves are insufficient. The deed also records the company’s then-current issued capital of EUR 155,153.36, consisting of 12,515,335 ordinary shares and 3,000,000 preferred shares allocated among series A and B (with an apparent typographical duplication of series A in the translation).

Filing Facts

CIK

1874252

Ticker

-

Form

8K

Source Type

fda

Accession

0001213900-26-048635

Alert Tier

5